日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Selective SIK2/SIK3 inhibition reprograms pro- and antiinflammatory pathways in myeloid cells, improving autoimmune disease outcomes

选择性抑制SIK2/SIK3可重编程髓系细胞中的促炎和抗炎通路,从而改善自身免疫性疾病的预后。

De Vos, Steve; Desroy, Nicolas; Bellaire, Susan J; Fernandes, Anna Pereira; Lavazais, Stéphanie; Merciris, Didier; Delachaume, Carole; Robin-Jagerschmidt, Catherine; Cosson, Adrien; Lazaryan, Angela; Van Osselaer, Nancy; Amantini, David; Peixoto, Christophe; Colli, Maikel L; Van Eeckhoutte, Thomas; Hakonen, Tiina; Constant, Magali; Garcia-Hernandez, Alberto; Barron, Rahul; D'Haens, Geert; Böcher, Wulf O

GLPG2737, a CFTR Inhibitor, Prevents Cyst Growth in Preclinical Models of Autosomal Dominant Polycystic Kidney Disease

CFTR抑制剂GLPG2737可阻止常染色体显性多囊肾病临床前模型中的囊肿生长

Dumont, Vincent; Meurisse, Sandrine; Verdonck, Katleen; Salgues, Valérie; Robert, Tiffany; Anquetil, Florence; Delachaume, Carole; Blanqué, Roland; Liekens, Daisy; Huang, Yan; Hu, Jinghua; Harris, Peter C; Nakhlé, Jessica; Conrath, Katja; Vandeghinste, Nick; Christophe, Thierry; Comas, Daniel

Discovery of Clinical Candidate GLPG3970: A Potent and Selective Dual SIK2/SIK3 Inhibitor for the Treatment of Autoimmune and Inflammatory Diseases

发现临床候选药物 GLPG3970:一种用于治疗自身免疫和炎症疾病的强效选择性双重 SIK2/SIK3 抑制剂

Christophe Peixoto, Agnes Joncour, Taouès Temal-Laib, Amynata Tirera, Aurélie Dos Santos, Hélène Jary, Denis Bucher, Wendy Laenen, Anna Pereira Fernandes, Stephanie Lavazais, Carole Delachaume, Didier Merciris, Corinne Saccomani, Michael Drennan, Miriam López-Ramos, Emanuelle Wakselman, Sonia Dupont